Hoosier Cancer Research Network (HCRN), formerly known as Hoosier Oncology Group, joined nearly 30,000 of the world’s leading cancer experts in Chicago recently for the Annual Meeting of the American Society of Clinical Oncology (ASCO).

Six HCRN studies were featured in oral abstract, poster highlights, and general poster sessions during the May 30-June 3 event. In addition, HCRN held face-to-face meetings for the gastrointestinal and genitourinary Clinical Trial Working Groups and for investigators participating in the GU12-160 study.

HCRN exhibit

Image 6 of 7

HCRN held a number of meetings with pharmaceutical, biotech, and research advocacy organizations, and provided support for Big Ten Cancer Research Consortium activities. HCRN serves as the Administrative Headquarters for the Big Ten CRC.

HCRN also participated as an exhibitor during ASCO.

HCRN posters and abstracts featured at ASCO 2014 include:

Oral Abstract Session

• A randomized double blind phase II trial of platinum (P) plus etoposide (E) +/- concurrent ZD6474 (Z) in patients (pts) with previously untreated extensive stage (ES) small cell lung cancer (SCLC): Hoosier Cancer Research Network LUN06-113. Sponsor investigator: Nasser Hanna, MD (Indiana University Melvin and Bren Simon Cancer Center)

Poster Highlights Session

• Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Hoosier Cancer Research Network BRE09-146. Sponsor investigator: Kathy Miller, MD (Indiana University Melvin and Bren Simon Cancer Center)Numerous abstracts were published utilizing matched pretreatment biopsies from BRE09-146.

General Poster Session

• Clinical phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in recurrent platinum-resistant ovarian cancer: Hoosier Cancer Research Network GYN10-149. Sponsor investigator: Daniela Matei, MD (Indiana University Melvin and Bren Simon Cancer Center)
• Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: Hoosier Cancer Research Network LUN 07-130. Sponsor investigator: Shadia Jalal, MD (Indiana University Melvin and Bren Simon Cancer Center)
• Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients with Germ Cell Tumors Undergoing 5-Day Cisplatin-Based Chemotherapy: Hoosier Cancer Research Network QL12-153. Sponsor investigator: Lawrence Einhorn, MD (Indiana University Melvin and Bren Simon Cancer Center)
• The Borealis-2 Clinical Trial: A Randomized Phase 2 Study of OGX-427 (Apatorsen) Plus Docetaxel Versus Docetaxel Alone in Relapsed/Refractory Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU12-160. Sponsor investigator: Noah Hahn, MD (Johns Hopkins Kimmel Cancer Center)

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has initiated more than 150 trials in a variety of cancer types and supportive care, resulting in more than 300 publications. More than 4,400 patients have participated in Hoosier Cancer Research Network clinical trials.